Stojnic, BojanGalmés, SebastiàSerrano, AlbaSulli, MariaSušak, LanaSeye, NdiobaPalou, AndreuDiretto, GianfrancoBonet, M LuisaRibot, Joan2024-10-092024-10-092023-12-08Stojnic B, Galmés S, Serrano A, Sulli M, Sušak, L, Seye N, et al. Glycosaminoglycan dermatan sulfate supplementation decreases diet-induced obesity and metabolic dysfunction in mice. Biofactors. 2023 Dec.https://hdl.handle.net/20.500.13003/20192https://hdl.handle.net/20.500.12105/23672Glycosaminoglycans are complex carbohydrates used as nutraceuticals for diverse applications. We studied the potential of the glycosaminoglycan dermatan sulfate (DS) to counteract the development of diet-induced obesity (DIO) using obesity-prone mice fed a high-fat diet (HFD) as a model. Oral DS supplementation protected the animals against HFD-induced increases in whole-body adiposity, visceral fat mass, adipocyte size, blood glucose levels, insulin resistance, and pro-inflammatory lipids levels in brown adipose tissue (BAT) and the liver, where it largely counteracted the HFD-induced changes in the nonpolar metabolome. Protection against DIO in the DS-supplemented mice occurred despite higher energy intake and appeared to be associated with increased energy expenditure, higher uncoupling protein 1 expression in BAT, decreased BAT "whitening," and an enhanced channeling of fuel substrates toward skeletal muscle. This work is the first preclinical study to examine the anti-obesity activity of DS tested individually in vivo. The results support possible uses of DS as an active component in functional foods/supplements to manage obesity and associated metabolic diseases.enghttp://creativecommons.org/licenses/by-nc-nd/4.0/research articleAttribution-NonCommercial-NoDerivatives 4.0 Internacional3806339110.1002/biof.20221872-8081BioFactors (Oxford, England)open access2-s2.0-851793683801116444400001L2026990531